Margaret Ragni on tranexamic acid to treat heavy menstrual bleeding

<p>Professor Margaret Ragni joins us to discuss the VWDMin study, published in <em>The Lancet Haematology</em>. In this phase 3, randomised, crossover trial, recombinant von Willebrand factor and tranexamic acid are used to treat heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA. <br/><br/>Read the full article:<br/><a href='https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae'>https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00119-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae</a></p><p>Continue this conversation on social!<br/>Follow us today at...<br/><a href='https://twitter.com/thelancet'>https://twitter.com/thelancet</a><br/><a href='https://instagram.com/thelancetgroup'>https://instagram.com/thelancetgroup</a><br/><a href='https://facebook.com/thelancetmedicaljournal'>https://facebook.com/thelancetmedicaljournal</a><br/><a href='https://linkedin.com/company/the-lancet'>https://linkedIn.com/company/the-lancet</a><br/><a href='https://www.youtube.com/thelancettv'>https://youtube.com/thelancettv</a></p>